Molecular Partners AG Market Cap ($125.91 Million)
Market Cap & Net Worth: Molecular Partners AG (MOLN)
Molecular Partners AG market cap. Molecular Partners AG (SW:MOLN) has a market capitalization of $125.91 Million (CHF99.59 Million) as of November 5, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #18119 globally and #184 in its home market, demonstrating a -17.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Molecular Partners AG's stock price CHF2.60 by its total outstanding shares 38305237 (38.31 Million). Also see Molecular Partners AG operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Molecular Partners AG Market Cap History (2015–2026)
Molecular Partners AG market cap history from 2015 to 2026. Data shows change from $1.69 Billion to $125.91 Million (-20.79% CAGR). Check Molecular Partners AG (MOLN) share price today for real-time trading data and today's change.
Molecular Partners AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Molecular Partners AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Molecular Partners AG to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
39.56x
Molecular Partners AG's market cap is 39.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.20 Billion | $23.04 Million | -$18.61 Million | 52.13x | N/A |
| 2017 | $1.27 Billion | $20.02 Million | -$25.43 Million | 63.63x | N/A |
| 2018 | $923.04 Million | $10.36 Million | -$37.04 Million | 89.14x | N/A |
| 2019 | $848.46 Million | $20.38 Million | -$36.29 Million | 41.63x | N/A |
| 2020 | $1.00 Billion | $9.34 Million | -$62.76 Million | 107.54x | N/A |
| 2021 | $862.99 Million | $9.33 Million | -$63.78 Million | 92.50x | N/A |
| 2022 | $298.32 Million | $189.56 Million | $117.85 Million | 1.57x | 2.53x |
| 2023 | $166.59 Million | $7.04 Million | -$61.98 Million | 23.67x | N/A |
| 2024 | $196.62 Million | $4.97 Million | -$54.04 Million | 39.56x | N/A |
Competitor Companies of MOLN by Market Capitalization
Companies near Molecular Partners AG in the global market cap rankings as of November 5, 2026. Also see Molecular Partners AG total assets for a full breakdown of the balance sheet.
Key companies related to Molecular Partners AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Molecular Partners AG (2015–2026)
Market capitalization of Molecular Partners AG from 2015 to today. Between 2015 and today, Molecular Partners AG's market cap moved from $1.69 Billion to $ 125.91 Million, with a yearly change of -20.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF125.91 Million | -23.19% |
| 2025 | CHF163.93 Million | -16.63% |
| 2024 | CHF196.62 Million | +18.02% |
| 2023 | CHF166.59 Million | -44.16% |
| 2022 | CHF298.32 Million | -65.43% |
| 2021 | CHF862.99 Million | -14.12% |
| 2020 | CHF1.00 Billion | +18.44% |
| 2019 | CHF848.46 Million | -8.08% |
| 2018 | CHF923.04 Million | -27.53% |
| 2017 | CHF1.27 Billion | +6.05% |
| 2016 | CHF1.20 Billion | -29.14% |
| 2015 | CHF1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Molecular Partners AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $125.91 Million USD |
| MoneyControl | $125.91 Million USD |
| MarketWatch | $125.91 Million USD |
| marketcap.company | $125.91 Million USD |
| Reuters | $125.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more